Silence Therapeutics Plc ADR (SLN)
NASDAQ
19.62
+0.04 (+0.20%)
Closed
Oct 20, 2026
Day's Range
19.5719.64
52 wk Range
4.1919.64
Financial Statements - SLN - Silence Therapeutics Plc ADR
Revenue
559.00K▼ 98.7%
Net Income
-88.61M▼ 95.6%Net Margin -15851.9%
EBITDA
-79.40M▼ 25.3%
Free Cash Flow
-62.32M▲ 8.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 559K | 43.25M | 25.37M | 17.50M | 12.41M | 5.47M |
| Cost of Goods | 215K | 11.81M | 10.31M | 10.88M | 7.45M | 3.76M |
| Gross Profit | 344K | 31.44M | 15.05M | 6.62M | 4.95M | 1.71M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -89.75M | -63.31M | -49.60M | -48.59M | -45.81M | -35.84M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -2.32M | 14.38M | -2.11M | 1.04M | -44K | -307K |
| Pre Tax Income | -88.60M | -44.46M | -50.31M | -47.36M | -45.85M | -36.04M |
| Income Tax | 11K | 845K | -7.04M | -6.87M | -6.44M | -3.49M |
| Net Income | -88.61M | -45.30M | -43.26M | -40.48M | -39.41M | -32.54M |
| EPS Basic | -1.89 | -0.99 | -1.167 | -1.257 | -1.329 | -1.194 |
| EPS Diluted | -1.89 | -0.99 | -1.167 | -1.257 | -1.329 | -1.194 |
| Basic Shares Outstanding | 47.23M | 46.25M | 28.80M | 25.93M | 23.88M | 21.95M |
| Diluted Shares Outstanding | 47.23M | 46.25M | 28.80M | 25.93M | 23.88M | 21.95M |
| Ebit | -89.75M | -63.31M | -50.27M | -47.32M | -45.84M | -36.02M |
| Ebitda | -79.40M | -63.37M | -47.66M | -47.88M | -45.37M | -35.22M |
| Net Income Continuous Operations | -88.61M | -45.30M | -50.31M | -47.36M | -45.85M | -36.04M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
